Albert Bourla says he was born and raised in Thessaloniki, the second-largest city in Greece.
“I'm Greek by nationality, so I was born and raised in the second largest city of Greece. It's called Thessaloniki.”

20 May 2022 · 34m · Albert Bourla, Bapu Jena · 23 quoted facts
Pfizer CEO Albert Bourla argues that the COVID vaccine came together quickly because of a few high-stakes leadership choices. He backed a new mRNA technology that had never produced an approved product. He also refused government money so his scientists could decide fast, with himself as the final decision-maker. He says the pandemic changed how people see the pharmaceutical industry.
The main tension is between caution and speed. Bourla first resisted mRNA, then accepted it after his scientists explained its speed and flexibility. He admits the CEO's job is lonely because no one can overrule him, and he nearly became too conservative. The episode asks whether the pandemic-era pace can carry over to cancer or heart disease, given that regulators must move as quickly as companies.
He challenged his scientists because mRNA had never delivered a product. He changed his mind because Pfizer had already been developing an mRNA flu vaccine with BioNTech, and the technology promised speed.
Bourla says it takes weeks rather than months to develop, and it avoids antibodies against a viral carrier like adenovirus that can weaken repeat doses. A new variant can be dropped into the same basic vaccine.
Bourla says taxpayer money comes with strings and oversight committees including the NIH and CDC. By declining it, he kept decisions in twice-weekly meetings where he made the final call.
Bourla says he first became overly conservative because there was no one above him to catch mistakes. A colleague reminded him that the board chose him for his appetite for risk.
He says drug companies had polled as badly as government, partly from pricing and promotion practices and partly because they are easy to blame. He argues the vaccine showed a good reason for the industry's existence.
CEO Albert Bourla says his scientists argued that mRNA was fast, easy to boost and easy to update for new variants, and Pfizer had already worked on an mRNA flu vaccine with BioNTech. He was reluctant because the technology had never produced a product.
Bourla says government funding would have come with strings attached and oversight from groups like the NIH and CDC. He wanted to avoid that bureaucracy so decisions could be made quickly in meetings he led.
Bourla says it took nine months instead of the usual eight years. Host Bapu Jena says a vaccine typically takes 5 to 10 years or longer, so Pfizer and other makers were far faster than normal.
Bourla says an independent committee reported an interim analysis in which the vaccine worked, with an efficacy of 95.6%. Efficacy is how much the vaccine reduces illness compared with no vaccine.
Bourla says a large part can be replicated through a culture of thinking big, but the pandemic was unique because everyone worked around the clock. He also says regulators like the FDA would have to move faster too.
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
Albert Bourla says he was born and raised in Thessaloniki, the second-largest city in Greece.
“I'm Greek by nationality, so I was born and raised in the second largest city of Greece. It's called Thessaloniki.”
Albert Bourla says he chose to become a veterinarian at age 18 because he loved animals and medicine.
“I became veterinarian. I was 18 when I made the choice, and I had an immense love for animals, and I liked medicine.”
Albert Bourla says he lived in nine cities across five countries during his career with Pfizer.
“I lived in nine different cities of five different countries with Pfizer.”
Albert Bourla says that about 17 of his nearly 30 years at Pfizer were spent in its animal health group rather than its pharmaceutical group.
“Most of my career in the 30 years, I'm having 30 years next year, 17 of them was in the animal health group, not in the pharma group.”
Albert Bourla became Pfizer's chief operating officer in 2018 and its CEO in 2019.
“In 2018, he became chief operating officer and the following year, CEO.”
Bourla says Pfizer was already working with BioNTech to develop an mRNA flu vaccine before choosing mRNA for COVID.
“we were working with this company, with BioNTech, to develop a flu vaccine for the rest of the years.”
Bourla says mRNA technology allows work to be done in weeks that takes months with other vaccine technologies.
“With mRNA, you can move extremely fast. You can do in weeks things that you take months with the other technologies.”
Bourla says adenovirus-based vaccines are harder to boost because the body also makes antibodies against the adenovirus carrier, which can reduce effectiveness.
“It's not easy to boost with adenovirus because every time you are boosting, you are not creating only antibodies against the coronavirus, but also against the adenovirus, which is the carrier.”
Bourla says mRNA vaccine manufacturing is not a biological production and can be adapted by swapping in new variants.
“You don't have some bacteria that they are making your vaccine eventually. So you can really plug and play in the mRNA.”
Bourla says an independent committee told Pfizer executives that the Phase 3 trial was successful in an interim analysis.
“They told us the news that it was successful in an interim analysis.”
Bourla says he was told the vaccine's efficacy in the interim analysis was 95.6.
“He said, so what is the efficacy? And then he told me 95.6.”
Bourla says that if the vaccine had failed, Pfizer would have written off $2.5 billion.
“one thing it is, okay, we failed, I will have to write off $2.5 billion.”
Bourla says he declined government funding because taking it would have required Pfizer's scientists to sit in numerous outside committees.
“by taking the money, I knew that my scientists will have to sit in numerous committees of people from wherever.”
Bourla says Pfizer's vaccine team met twice a week, with him making the final decision at those meetings.
“So I said, it's you and me. So we will all be meeting twice a week, everybody who is needy for a decision.”
Host Bapu Jena says vaccines typically take 5 to 10 years to develop and manufacture, and often longer.
“It typically takes 5 to 10 years to develop and manufacture a vaccine, and often it takes even longer.”
Bapu Jena says Pfizer and other drug makers brought COVID vaccines to market in less than a year.
“Pfizer and the other pharmaceutical makers brought their COVID vaccines to market in less than a year.”
Bourla says Pfizer made its COVID vaccine in nine months, compared with about eight years normally.
“if we were able to make a vaccine in nine months instead of eight years”
Bapu Jena says that in the initial approval study, Paxlovid taken early cut the risk of serious illness or death from COVID by around 90% in high-risk unvaccinated people.
“When they took Paxlovid early in their infection, it reduced the risk of serious illness or death from COVID by around 90%.”
Bourla says Pfizer's clinical trial data showed only a very small percentage of patients with rebound symptoms after taking Paxlovid.
“We have looked into the data that we have in our clinical trial, and we saw a very small percentage of this occurring.”
Bapu Jena says only around one-third of Americans had received a booster dose at the time of the interview.
“It's been a struggle to get some people to take their first, second, and now third or fourth COVID vaccines. Only around one-third of Americans are boosted.”
Bapu Jena says Bourla told him Pfizer expected to submit data on a three-dose series for children under five, with a third dose appearing to add substantial protection.
“Pfizer expects to submit its data this month on the efficacy of a three-dose series for these kids, and that adding a third dose seemed to provide substantially more protection against COVID compared to just two doses.”
Bourla says the reputation of pharmaceutical companies before the pandemic was as bad as that of government in polls.
“The reputation of the pharmaceutical companies was as bad as the reputation of government in polls.”
Albert Bourla wrote a book titled Moonshot, Inside Pfizer's Nine-Month Race to Make the Impossible Possible.
“And check out his book, Moonshot, Inside Pfizer's Nine-Month Race to Make the Impossible Possible.”
Bourla describes his unusual path from a veterinary PhD in Greece to a career at Pfizer. His animal-health background shaped how he approached the pharma business.
“I became veterinarian. I was 18 when I made the choice”
Bourla explains how the lack of anyone above him made him overly cautious at first. Understanding this helps explain how he later made bold bets.
“You can only feel it when you're a CEO because you're alone.”
Returning from a canceled congress, Bourla set priorities for protecting staff, keeping hospital drugs supplied and developing vaccines and treatments.
“And on the plane, I realized that that's affecting the whole world.”
Bourla describes challenging his scientists on mRNA and then being convinced by its speed, boosting and manufacturing advantages.
“I challenged the decision. I said, are you kidding me?”
Bourla recounts waiting for the independent committee's interim results and hearing the efficacy figure. It was the payoff for the risky platform choice.
“I was, I jumped from my chair. It was an amazing moment.”
Bourla calls this the second-hardest decision of the pandemic. It kept decision-making inside Pfizer, free of outside committees.
“Not to take the money from the government.”
Bourla considers applying the nine-month vaccine speed to other diseases and says regulators would need to change too.
“if we were able to make a vaccine in nine months instead of eight years”
Bourla expects the virus to persist for years and says treatments are as important as vaccines. He addresses rebound symptoms after Paxlovid.
“We must have a vaccine that is administered annually.”
Bourla says the industry's image was poor before COVID. He argues the vaccine showed its value while warning that trust must be earned daily.
“we were able to show that there is a good reason for our existence”
Your business relies on technology every day, but how confident are you in the security behind it? As your business evolves, so do the cybersecurity challenges that come with it. That's why BPM's Cybersecurity Risk Assessments help leaders better understand cyber risk, identify vulnerabilities, and develop a practical roadmap for stronger security. Build confidence in your cybersecurity strategy. Learn more at bpm.com slash cyber. What do I gift my mom and nieces? Walmart has top brands you know Like Ninja, Disney, Lego Oh, dad loves music Sonos can bring his songs to life With sound that hits just right
And my coffee-obsessed bestie
DeLonghi Brews Coffee Ride for morning's extra price All those great brands at Walmart? Who knew? We knew, now you do too Shop gifts they'll love at Walmart Like most of us, Dr. Albert Bourla remembers the first time he heard about a novel coronavirus that was spreading in China.
The first thing that came to my mind is I have thousands of people working for us in China. I had manufacturing sites, I had research centers in China. And we were just monitoring the situation, but with an eye that this is only China.
But as the coronavirus began its march around the world in early 2020, it became clear that the disease it caused, COVID-19, would be impossible to contain.
In February, things started to getting more and more visible. From Asia, things went into Europe and went straight to Italy. And I started worrying about it. And I traveled there a week after. And that is when I realized things are going to be very bad. My name is Albert Bourla. I'm the CEO of Pfizer since 2019.
As he traveled home from a canceled conference in Greece, Albert Bourla was already forming a plan.
I decided to take the plane and go back immediately. And on the plane, I realized that that's affecting the whole world. So I was having time to reflect what we need to do and what is our role.
From the Freakonomics Radio Network, this is Freakonomics MD. I'm Bapu Jena. I'm a medical doctor and I'm also an economist. Today, you'll hear my conversation with someone who, in a way, also straddles these two worlds. And a few other ones, too.
When I was elected as CEO, the first statement that I made to my board members was, only in America.
We'll talk about Albert Bourla's unusual path to this high-ranking role and about his new book, Moonshot. In it, he describes developing a COVID vaccine in record time. But not just any vaccine.
My scientist came and said, let's try mRNA. And that was very counterintuitive. I challenged the decision. I said, are you kidding me?
We'll also explore why decision-making in general can be so hard, even for, and maybe especially for, people at the very top.
When I took the job, I felt that there is something that you can be prepared for, and I found it very challenging. And this is that the buck stops here.
And Albert tells me why the way people view his industry might be changing.
In the pandemic, in a very profound way, we were able to show that there is a good reason for our existence.
What do you prefer to be called? Do you want to be called Dr. Burla, Albert, Chief Burla, Chief Albert? You just tell me. Usually it's Dr. Burla, but for you, Dr. Albert. Dr. Albert, okay.
No, no, no, I'm kidding. Don't dare. No, Albert, please.
If there's a typical route to becoming CEO of one of the largest and most influential pharmaceutical companies in the world, it feels like Dr. Albert Bourla, or Albert, didn't take it.
I'm Greek by nationality, so I was born and raised in the second largest city of Greece. It's called Thessaloniki. Actually, it's a very historic city. It's not very well known, but it was named after the sister of Alexander the Great. And it was founded 2 ,300 years ago. So it's a very old city. I became veterinarian. I was 18 when I made the choice, and I had an immense love for animals, and I liked medicine. And that's what I felt is the best combination of the two.
So when you were six years old, you didn't anticipate becoming CEO of a drug company. Would that be accurate? Not of Pfizer, but I knew that I would be famous and great.
Actually, when I was six years old, I remember telling my father I wanted to be Tarzan. And when he asked me why, I said, because I think Jane is very beautiful.
Eventually, he got over Jane, as one does, and obtained his veterinary degree. But Albert was beckoned by the world of research, which is exactly where he thought he'd stay.
I finished my PhD and all I wanted was to make a career in academia. I never felt that I would do something else. And I never thought that I would leave my city, Thessaloniki. Pfizer came with their animal health business. It was in Athens. And they tried to recruit me and they tried really hard. So they put an offer in front of me I couldn't resist. So that's how I joined Pfizer. I didn't know two things.
One is that within a few months, I will fall in love with the private sector, what I thought was the Antichrist at the moment.
I thought you were telling me how you met your wife, but okay. This is your second love that you fell in love with first, I guess. My wife is the big love. That was the first love.
And I decided to stay. So that's the first thing that I didn't know. The second thing that I didn't know is that this first reluctant relocation will be the first of nine I did with the company. I lived in nine different cities of five different countries with Pfizer. Most of my career in the 30 years, I'm having 30 years next year, 17 of them was in the animal health group, not in the pharma group. I grew up in the ranks of a division very small within Pfizer.
We had to fight to get resources in very different ways. We had to learn to do things in a very nimble way. So when I joined the pharma, I was really able to see things that others that grew up in this business, they couldn't. I think that helped me be different at least.
As Albert moved from city to city and country to country, he climbed the ranks within Pfizer. In 2018, he became chief operating officer and the following year, CEO. Do you enjoy what you do?
I do. I do. I don't enjoy losing. I hear many people that are saying, you know, I like challenges. Well, I like challenges when I can win. I don't like a challenge when we fail. I like when the study shows that the cancer patients lived more on this drug. And when I see that we didn't have an impact, you know, it's a tremendous disappointment. You want to be the one that will present the solution to the cancer patients.
You can stand up and say to a father or mother that I have a solution. Don't worry, you will see the graduation of your daughter or the wedding of your son. It's very bitter, the sense of failure in clinical development.
Anybody who takes care of patients would probably say the same thing because there's a very direct attachment between who they're taking care of. They see the pain, they see the hope. And when things don't work out, it's very difficult to sort of remove yourself from that. But, you know, doctors and other health care providers probably learn how to detach themselves in that way. You're obviously many, many levels higher, but the impact potentially is much, much greater.
You're not talking about one patient, but thousands or maybe millions of people who are affected by an up or down outcome on a drug. But still, that component is there for you. Oh, very accurate. Very accurate.
During the studies, during the whole development of the program, usually I meet with a lot of patients. So we know people. We know people that participate. And, you know, it's really very painful when you fail. It is very, very rewarding when you are successful. I became CEO in 2019. I thought that I was preparing for that the last two, three years. As part of that process, I learned not only to do a lot of the parts of the business, But I learned to speak to investors, to the press, to politicians, to the field, to do all the things that maybe a CEO will do.
I was very surprised, however, that when I took the job, I felt that there is something that you can be prepared for. And I found it very challenging. And this is that the buck stops here. You can only feel it when you're a CEO because you're alone. You're the ultimate decision maker. Before, I knew that there was someone above me that can stop me. if there is something stupid. So there was filters. Now I felt suddenly that there is no one that can do that.
So I started being very conservative and starting thinking and double guessing two, three times everything until someone told me, look, it's not the conservatives that brought you here. It is that the board appreciated that you have an appetite for risk, that you are thoughtful. They trust you. So don't be conservative. And then this is when I started realizing that I need to adapt to this level of responsibilities and do the things that I know or I feel are the right things to do.
That was the biggest thing of the adjustment.
One of the most compelling parts of the book Moonshot was sort of how you describe the early stages of the pandemic when we're starting to hear news about a new virus in China. The genetic sequence was being identified. Can you walk me through that time for you, both as an executive at Pfizer and also personally?
The first thing that we learned with this pandemic was not a pandemic, but was a situation in China. We realized that in China there is a health issue. And that was the first thing that came to my mind as the CEO of Pfizer. I have thousands of people working for us in China. I had manufacturing sites, I had research centers in China. So we formed a task force to see how we can protect them, what needs to be done.
So we started implementing some measures. For the first time, we told them, stay home. It was unthinkable for us. And we were just monitoring the situation, but with an eye that this is only time. In February, things started to getting more and more visible and particularly we started seeing from Asia, things went into Europe and went straight to Italy. And I started worrying about it. I had a discussion with our board that was in February. Still, no one was thinking that this is anything like that, right?
We are all in the meeting room. And I traveled there a week after, and that is when I realized things are going to be very bad, because I am traveling to participate in a Congress. Suddenly, from Italy, things are moving to other European countries, and the Congress is canceled. So I decide to take the plane and go back immediately. And on the plane, I realized that that's affecting the whole world. So I was having time to reflect what we need to do and what is our role, and I wrote down three things.
The first was what we do with our people. So we need to find solutions how to make sure that they are not going to get affected. The second was the hospitals and ICUs. I saw in China that they had tremendous search of hospitalization. And when I asked our local guys, they told me that the main problem over there, it is that people die because they can't give them enough hospital care, because they don't have enough beds, because they are all getting sick at the same time.
But this made me think that we are one of the biggest suppliers of injectable products in the world. Products that are used in ICUs are made by Pfizer. And I was thinking, how can I maintain a supply that the demand will go not two or three, 40, 50 times in some medicines, very specialized medicines? How to maintain that and at the same time work under social distancing type of isolation? That was a very big challenge for us.
And the third was I wrote down, we need to work on vaccines and treatments.
Why did you choose the mRNA platform versus any number of ways you could have tried to develop a vaccine?
I was very reluctant to choose it. Moderna, the decision for them would be, shall we do a vaccine or not? There was only one way they can do it. mRNA, this is where they are good. Ourselves, we were mastering all technologies. But my scientist came and said, let's try mRNA. And that was very counterintuitive. I challenged the decision. I said, are you kidding me? you want to put in a pandemic all our bets into a technology that never delivered a product?
Why don't we go with something else? And we sat down to discuss it. So I was convinced by their arguments. The first one was we were working with this company, with BioNTech, to develop a flu vaccine for the rest of the years. and we had matured this technology significantly to make a flu vaccine. So they were feeling that it's ready to deliver a product. The second is we focused on what are the benefits if we are successful.
And the benefits were very, very impressive. With mRNA, you can move extremely fast. You can do in weeks things that you take months with the other technologies. So that was a very big plus. With mRNA, you feel that you can boost as many times as you want. It's not easy to boost with adenovirus because every time you are boosting, you are not creating only antibodies against the coronavirus, but also against the adenovirus, which is the carrier.
And that could reduce the effectiveness of your vaccine. In terms of variants, you want it to be able to scale up manufacturing in a quick way. And in the mRNA, it's not a biological production. You don't have some bacteria that they are making your vaccine eventually. So you can really plug and play in the mRNA. You can take a new variant, put it in the same vaccine, and then the vaccine is completely different, although it is basically everything the same vaccine.
So all of that were the things that convinced me to go with this bet. But it was a very difficult decision for me.
Coming up after the break, Albert and I reflect on some other difficult and big decisions he's made during the pandemic.
We were on a race. We wanted to bring a vaccine and actually I wanted to be the one that we will bring the first one. Also, how will we coexist with this virus going forward? I think the most likely scenario is that the virus will be around for years.
I'm Bapu Jena and this is Freakonomics MD. More of my chat with Pfizer CEO Albert Bourla after the break. That's PG &E on the front lines for us all. Residential blended electric rates have decreased five times since January 2024, reducing rates 13 % since then for customers who get both energy supply and delivery from PG &E. For PG &E's most vulnerable customers, residential blended electric rates are 23 % lower than in January 2024. This message was paid for by shareholders.
Your business relies on technology every day, but how confident are you in the security behind it? As your business evolves, so do the cybersecurity challenges that come with it. That's why BPM's Cybersecurity Risk Assessments help leaders better understand cyber risk, identify vulnerabilities, and develop a practical roadmap for stronger security. Build confidence in your cybersecurity strategy. Learn more at bpm.com slash cyber. What do I gift my mom and nieces? Walmart has top brands you know, like Ninja, Disney, Lego.
Oh, dad loves music.
Sonos can bring his songs to life with sound that hits just right.
And my coffee-obsessed bestie.
DeLonghi Brews Coffee Ride for morning's extra price.
All those great brands at Walmart? Who knew? We knew, now you do too. Shop gifts though love at Walmart. It typically takes 5 to 10 years to develop and manufacture a vaccine, and often it takes even longer. It's a process that entails not just making the vaccine itself, but testing it in phase 1, 2, and 3 trials that assess things like safety, dosage, immune response, and efficacy. Then there's the regulatory process, which can also take months, if not years.
And finally, if it's approved, the vaccine has to be manufactured at scale. Pfizer and the other pharmaceutical makers brought their COVID vaccines to market in less than a year. So what was it like to find out that the mRNA vaccine had worked? What was the email like when you got the first results from the Phase 3 trial? How long did that euphoria last? Was it like an hour, two hours, three hours?
No, that lasted quite a bit because I didn't allow people to communicate to me after a while. It was not an email. It was actually live, waiting to hear the numbers. We gathered five of us in a very small office in a Connecticut site that we have. We were waiting to hear back when this committee, which is an independent committee of experts, will unblind the data and see what's going on. They were late. So that makes you worry.
You always think if they are late, that's a bad news. Then it was 222, something like that. But they sent an email. We have the data. Please assemble. So we went to a meeting room. They were late. We were in a Zoom call and they were not coming. So again, I was very nervous. I would say I think they do it on purpose to punish me for everything I did to them. them all these months, torturing them with, I want it faster, I want it faster.
They told us the news that it was successful in an interim analysis. I was, I jumped from my chair. It was an amazing moment. And then 10 minutes later, they, in a smaller group even, they told us what is the efficacy. That was the most material information in the world at that time. And then someone told me the numbers and I didn't hear well. He told me 90 and I heard 19. And I said, 19 or 90?
He said, 90. I said, 9, 0? Yes. He said, so what is the efficacy? And then he told me 95.6. And I looked at our legal counsel and said, what is this? I mean, this is... Then I started going from there very fast to communicate it the next day, 6 o 'clock in the morning.
The decision to go with the mRNA platform for Pfizer's COVID-19 vaccine might seem obvious in retrospect, as good decisions do. At the time, though, no one at Pfizer, including Albert, could be sure that risking so much time and so many resources would pay off. It's hard to consider the alternative.
It would be a very big disappointment. I think if we were not successful, clearly Modern also wouldn't be successful a little bit later. And the world will be in a very different place right now. So one thing it is, okay, we failed, I will have to write off $2.5 billion. dollars, and that's nothing compared to what the world would be entering into a phase of darkness and, I mean, unbelievable. So, thank God it was positive.
Albert told us that the decision to go with the mRNA platform was the hardest decision he had to make as CEO. So, I wondered, what was the second hardest decision you had to make during the pandemic?
Not to take the money from the government. Again, as a CEO, it was a time that it was the operation worst pit and they were giving money like there's no tomorrow. Whoever was raising their hand could take as much as they wanted because people were scared. Now, why I didn't take the money was because when you take money from someone, it never comes without strings attached. the fact that these are taxpayers' money, they better check where the money are going and they better check how you spend them.
But this is what I wanted to avoid. We were on a race. We wanted to bring a vaccine and actually I wanted to win us. I wanted to be the one that we will bring the first one, this vaccine. And by taking the money, I knew that my scientists will have to sit in numerous committees of people from wherever. NIH, Operation Workspeed, CDC, everyone in existence to be able to make a decision. I didn't want that.
I wanted to be isolated from all of this bureaucracy. We had enough bureaucracy internal of the company. So I said, it's you and me. So we will all be meeting twice a week, everybody who is needy for a decision. And we will discuss it all together. and then there is someone who can make a call in this meeting. And it is me, PAMA. So I could hear everyone and then we move, we move, we move. This is how we were able to move fast.
Prior to the pandemic, have you ever made anything move so quickly? No. With any other disease or product?
We had successes in our research programs, but we never have something of that speed.
It makes me think, though, what you were able to do because the stakes were so high in the pandemic. Does that tell you anything about whether we should or can move quicker in other areas?
Well, if we were able to make a vaccine in nine months instead of eight years, you can tell what that could be the impact if we were making a heart attack treatment or a cancer treatment or rheumatoid arthritis treatment or atopic dermatitis treatment, all of these diseases that are a big, big burden to humankind. It's not easy, though. One, it is that the conditions that we were living were truly unique. So it was not only that we put all the money and all the resources, but everybody put their time 24-7.
They couldn't sleep for three, four weeks, maybe. difficult to replicate something like that. So I think you can replicate a very large part of it. And it is a question of culture, how to think big, how to do things out of the box. And it's not only us. We'll require regulators to do the same. You need two to tango. Also, FDA and regulators, they will have to do the same. we can't just say now let's go back to normal we'll be again three, four months.
When you saw that you can do it in a way.
What does the future hold for the pandemic? What is your sort of like lay of the land for the next few years and maybe even further? Do you have a sense?
We must have a vaccine that is administered annually. If we have vaccines that either we don't know how long will last or we know that will last let's say a few months the compliance of the people with the recommendation of the health authorities will go down. I'm certain. I think the most likely scenario is that the virus will be around for years. Thank God we have treatments also now which we didn't have before. It's not only the vaccine.
I think the situations that we are entering now is even more important than treatment. But those that are getting sick they will not end up in hospitals and die and will be just a few days home hopefully for most of them, not all, but for most of them. But this is where I think things are going. So we need to make sure that we have treatments available and we need to make sure that we develop a vaccine that lasts a year.
It's been a struggle to get some people to take their first, second, and now third or fourth COVID vaccines. Only around one-third of Americans are boosted. But there's still an entire group for whom vaccination hasn't even been an option, children under five. Albert and I talked about this too, and he said Pfizer expects to submit its data this month on the efficacy of a three-dose series for these kids, and that adding a third dose seemed to provide substantially more protection against COVID compared to just two doses.
Also, the treatment Albert just mentioned refers to an antiviral drug from Pfizer that you've probably heard of. It's called Paxlovid. The initial approval study included symptomatic unvaccinated people with COVID who were at high risk of severe disease. When they took Paxlovid early in their infection, it reduced the risk of serious illness or death from COVID by around 90%. After briefly being in short supply earlier this year, it's now readily available for high-risk COVID patients over 12 years old.
It's an important tool in the fight against COVID, but I wanted to ask Albert about some recent news concerning the drug. Because the makeup of people using the drug now, mostly vaccinated people, isn't the same as the group that was studied in the trial. I'm sure you have seen these reports of people who take a course of Paxilvid for five days. They get an improvement in symptoms, they test negative, but then they test positive and they actually notice a rebound of symptoms after day five.
I know you're not a virologist, but I'm curious what you think is going on.
We are looking into it. We have looked into the data that we have in our clinical trial, and we saw a very small percentage of this occurring. But I think the general explanation, it is that without myself being a virologist, is that PaxClovid is not 100 % effective, right? It's reducing hospitalization and death 90%. And also we know also from the studies that it's not reducing to zero the viral load. Your immune system should also do the job after this dramatic help.
So the remaining virus, you should clean it. Not everybody will do that because not every individual is the same. So I think everything will happen in biology. But 90 % of the people will not go to hospital. Or we will reduce the number of people that go into hospital by 90%. Let's focus on how many lives are saved.
I want to kind of reflect a little bit on your particular sort of personality and role as a spokesperson for the company. I mean, you have a different background than many CEOs do. And I'm curious, how do you think that's helped you?
I come from humble beginnings. I come from a country that has very great heritage and gave democracy to the world, but is not known for giving a lot of CEOs to the world in the modern history. I have a very heavy accent. when I was elected as CEO and they called me in the boardroom to tell me that I was elected. The first statement that I made to my board members was only in America.
There's a perception of pharma that's often historically been quite negative. Why do you think that is? And has that changed as a result of the pandemic?
It was very bad. The reputation of the pharmaceutical companies was as bad as the reputation of government in polls. It's actually, in many cases, government was higher. How can you lose from government in that? It's admirable. It was for multiple reasons. Let me start. It was because a lot of the companies were not doing the right thing at certain points. We start with the responsibility of us not doing the right thing. pricing, in the way that they were promoting things.
The second is that health is in the forefront of every political debate. And in the political debates, it's easy to find someone to blame. And it's much easier to blame someone who is unknown, that is not FACE, a pharma company, than, for example, to blame a hospital. when you know the nurses, you know the doctors. So for multiple reasons, the reputation was very bad. And the pharma was not able to demonstrate to the world the value that they can bring until pandemic.
In the pandemic, in a very profound way, we were able to show that there is a good reason for our existence. And there are so many good things that can come out of us. And that raised the reputation very, very high. Now, the reputation is something that you are earning in drops, typically. But you can lose in buckets. But I know that we need to earn this trust and reputation every single day.
So all four of us in my household, my wife who's a doctor and two kids, actually have COVID this week. And I'm sure you're thinking about Paxilvid and kids. But I will tell you that I have a new discovery that you should consider. And it's an iPad. I have found that the iPad reduces symptoms of the kids. And there is an interaction with ice cream and popsicles that I'm sure is perhaps maybe 25 % as effective as Pax Levit or any other drugs in kids.
So you just keep that in the back of your mind for a little bit.
I'm going to try to make a deal with Apple to see if we can bring that to market.
Yeah. All right. Perfect. It might be hard to get an IP on it, but you could try. All right. Well, thank you so much. I appreciate this. Thank you.
Thank you, Bapu. And I enjoyed this discussion a lot.
That's it for today's show. My family and I are feeling better now, by the way, and we've managed to wean the kids off their iPad ice cream regimens. I want to thank Dr. Albert Bourla for taking the time to talk with me. And check out his book, Moonshot, Inside Pfizer's Nine-Month Race to Make the Impossible Possible. It's really quite a page-turner, even though we already know the ending. Next week on Freakonomics MD, a rebroadcast with some twists of an earlier episode on whether barbershops can improve health care and health outcomes for black men.
I noticed some guys would come and get their hair cut and stay. And you said to yourself, why is he still here? Well, there's a vibe here. There's a community here. There's a conversation going on. This is the community hub. We'll also discuss some new research of mine that looks at why representation is critical in medicine and why it can be so hard to find. That's coming up next week on Freakonomics MD. Please let me know what you thought about today's episode.
I'm at bapu at freakonomics.com. If you want to learn more about the show or check out the transcript for this episode, that's all at freakonomics.com. Thanks for listening.
Neil Carruth, Gabriel Roth, Greg Rippin, Rebecca Lee Douglas, Zach Lipinski, Morgan Levy, Ryan Kelly, Jasmine Klinger, Emma Terrell, Lyric Baudich, Jacob Clemente, and Stephen Dupner. Original music composed by Luis Guerra. If you like this show or any other show in the Freakonomics Radio Network, please recommend it to your family and friends. That's the best way to support the podcasts you love. As always, thanks for listening.
So how do you unwind after a busy day? Do you have time to relax in the evenings at all or no?
Oh, yes, I do have time to relax. I wish I could say I'm reading German literature, but I'm not that sophisticated of philosophy.
So you watch Netflix? I watch Netflix a lot. All right, so you watch Netflix. By the way, you don't share your Netflix passwords with other family members, right? Just to be clear. It was stolen, unfortunately. It was stolen. Yeah, exactly. I say it was stolen by my close personal friends and family.
The Freakonomics Radio Network. The hidden side of everything. Stitcher.
your business relies on technology every day but how confident are you in the security behind it as your business evolves so do the cyber security challenges that come with it that's why bpm's cyber security risk assessments help leaders better understand cyber risk identify vulnerabilities and develop a practical roadmap for stronger security build confidence in your cyber security strategy. Learn more at bpm.com slash cyber. For adults with Crohn's disease or ulcerative
colitis symptoms, every choice matters. Tremphaya offers self-injection or intravenous infusion from the start. Tremphaya is administered as injections under the skin or infusions through a vein every four weeks, followed by injections under the skin every four or eight weeks. If your doctor decides that you can self-inject Tremphaya, proper training is required. Tremphaya is a prescription medicine used to treat adults with moderately to severely active Crohn's disease and adults with moderately to severely active ulcerative colitis.
Serious allergic reactions, increased risk of infections or lower ability to fight them, and liver problems may occur. Before treatment, get checked for infections and tuberculosis. Tell your doctor if you have an infection, flu-like symptoms, or need a vaccine. Explore what's possible. Ask your doctor about Tremphaya today. Call 1-800-526-7736 to learn more or visit trimfiradio.com.